|
Age (years), mean (SD)
|
52 (9.9)
|
|
Females (percent)
|
22 (88%)
|
|
Race n (%)
|
|
Caucasian
|
10 (40%)
|
|
Black
|
4 (16%)
|
|
Hispanic
|
5 (20%)
|
|
Asian
|
4 (16%)
|
|
Other
|
2 (8%)
|
|
Seropositive n (%)
|
22 (88%)
|
|
Disease Duration (years), mean (SD)
|
10.4 (9.7)
|
|
BMI, mean (SD)
|
31.0 (10.8)
|
|
Prednisone at Baseline n (%)
|
7 (28%)
|
|
csDMARDs at Baseline n (%)
|
18 (72%)
|
|
Methotrexate
|
13 (52%)
|
|
Sulfasalazine
|
4 (16%)
|
|
Hydroxychloroquine
|
4 (16%)
|
|
Leflunomide
|
4 (16%)
|
|
bDMARDs before Baseline n (%)
|
|
TNF inhibitor
|
8 (32%)
|
|
IL-6 inhibitor
|
1 (4%)
|
|
Anti-CTLA4-IgG
|
2 (8%)
|
|
None of the Above
|
14 (56%)
|
|
Comorbidities (number), mean (SD)
|
3.8 (2.6)
|
